51-48-9

L-Thyroxine (NSC 36397) is the major hormone derived from the thyroid gland. L-Thyroxine (NSC 36397) is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. L-Thyroxine (NSC 36397) is released from thyroglobulin by proteolysis and secreted into the blood. L-Thyroxine (NSC 36397) is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

L-Thyroxine-13C6 is the 13C labeled compound of L-Thyroxine. L-Thyroxine has a CAS number of 51-48-9. Levothyroxine is the major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

D-Thyroxine (Dextroxin) could lower cholesterol and also increases hepatic lipase which in turn improves utilization of triglycerides, leading to improve apolipoprotein E cholesterol particles.

L-Thyroxine sodium (LT4 sodium), the major hormone derived from the thyroid gland, is the agonist of Thyroid hormone receptor alpha and beta.

L-Thyroxine sodium xhydrate is a synthetic thyroid hormone used in the treatment of hypothyroidism.

L-Thyroxine sodium salt pentahydrate (Sodium levothyroxine pentahydrate) is a thyroid hormone with anticholesterol activity that inhibits the release of thyroid hormones from thyroid cancer nodules and is used in immune and endocrine disorders such as hypothyroidism, myxedema, cretinism and obesity. diseases, such as hypothyroidism, myxedema, cretinism and obesity.

L-Thyroxine-13C9,15N is intended for use as an internal standard for the quantification of L-thyroxine by GC- or LC-MS. L-Thyroxine is a synthetic form of the thyroid hormone thyroxine. In vivo, L-thyroxine (0.9 and 2.7 μg) inhibits synthesis and release of thyrotropin induced by thyrotropin-releasing hormone from the anterior pituitary in mice. It also reverses decreases in levels of circulating thymic serum factor (FTS) and the number of T rosette-forming cells in an old age-induced mouse model of hypothyroidism. Formulations containing L-thyroxine have been used in the treatment of hypothyroidism.